Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 21;4(11):100544. doi: 10.1016/j.jhepr.2022.100544

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 2 — Changes in liver biomarkers.

Mean (SEM) levels from baseline to Day 84 and percent reduction on Day 28 in (A–C) GGT, (D–F) ALP, (G-I) ALT, and (J–L) total bilirubin. Patients who achieved GGT <65 U/L, ALP <1.67× ULN (<174 U/L), ALT <45 U/L, or total bilirubin <0.6× ULN (12.6 μmol/L) by Day 28 were considered to have normalised response. ALP, alkaline phosphatase; ALT, alanine aminotransferase; GGT, γ-glutamyl transferase; ULN, upper limit of normal.

Fig. 2 — Changes in liver biomarkers.

Mean (SEM) levels from baseline to Day 84 and percent reduction on Day 28 in (A–C) GGT, (D–F) ALP, (G-I) ALT, and (J–L) total bilirubin. Patients who achieved GGT <65 U/L, ALP <1.67× ULN (<174 U/L), ALT <45 U/L, or total bilirubin <0.6× ULN (12.6 μmol/L) by Day 28 were considered to have normalised response. ALP, alkaline phosphatase; ALT, alanine aminotransferase; GGT, γ-glutamyl transferase; ULN, upper limit of normal.